Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays, which decreases the relative dose intensity of treatment. Both scenarios can be associated with reduced survival in patients with cancer, according to Jeffrey Crawford, MD, Chief, Division of Medical Oncology, Professor of Medicine, Duke Cancer Institute.
At the NCCN 19th Annual Conference, Dr. Crawford and George M. Rodgers, MD, PhD, Professor of Medicine, Huntsman Cancer Institute at the University of Utah, discussed the appropriate use of myeloid growth factors (MGFs) to prevent neutropenia and the value of using intravenous (IV) iron for cancer-related anemia.
Dr. Crawford has disclosed that he has received grants or research support from Amgen Inc., AstraZeneca Pharmaceuticals LP, GTx, Inc., and MedImmune Inc., and has served as a scientific advisor for Bayer HealthCare, Boehringer Ingelheim GmbH, Celgene Corporation, Eli Lilly and Company, Gilead Sciences, Hoffmann-La Roche, Merrimack Pharmaceuticals, ONO Pharmaceutical Co. Ltd., and sanofi-aventis US. Dr. Rodgers has disclosed that he has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kuderer NM, Dale DC, Crawford J et al.. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–2266.
Lyman GH, Kuderer NM, Crawford J et al.. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917–1927.
Gilreath JA, Sajeser DS, Jorgenson JA, Rodgers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008;6:577–584.